GB Sciences, Inc. (OTCQB: GBLX) and Louisiana State University (“LSU”) AgCenter recently announced an agreement with GB Sciences Louisiana, LLC, a wholly owned subsidiary of GB Sciences, Inc., to produce medical cannabis products for qualifying patients. The agreement, conducted under compliance with the Alison Neustrom Act, will allow GB Sciences to produce medical cannabis under the AgCenter’s license. In a news release, GB Sciences, Inc. stated that the agreement is “historic” and creates a formidable partnership. GB Sciences is a publicly traded cannabis company firmly rooted in science. This partnership with LSU, a major research university, is dedicated to advancing the understanding of the cannabis plant and offering cannabis-based medicines to patients of Louisiana.
To view the full article, visit http://cnw.fm/iT6w2
About GB Sciences, Inc.
GB Sciences, Inc. (GBLX) is a diverse cannabis company focused on standardized cultivation and production methods, as well as biopharmaceutical research and development. The company’s goal is to create safe, standardized pharmaceutical-grade cannabinoid therapies that target a variety of medical conditions. For more information, visit www.GBSciences.com
More from CannabisNewsBreaks
About CBDWire
CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com
